Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03290560




Registration number
NCT03290560
Ethics application status
Date submitted
18/09/2017
Date registered
25/09/2017
Date last updated
31/03/2022

Titles & IDs
Public title
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
Scientific title
A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke
Secondary ID [1] 0 0
DM199-2017-001
Universal Trial Number (UTN)
Trial acronym
ReMEDy1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Ischemic Stroke 0 0
Condition category
Condition code
Stroke 0 0 0 0
Haemorrhagic
Stroke 0 0 0 0
Ischaemic
Neurological 0 0 0 0
Other neurological disorders
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Recombinant human tissue kallikrein
Other interventions - Placebo

Experimental: Recombinant human tissue kallikrein - A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.

Placebo Comparator: Placebo - A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.


Treatment: Drugs: Recombinant human tissue kallikrein
Recombinant human tissue kallikrein

Other interventions: Placebo
Placebo Comparator: Phosphate buffered saline
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with treatment-related adverse events as assessed by CTCAE v4.3
Timepoint [1] 0 0
90 Days
Secondary outcome [1] 0 0
Changes from baseline to Day 90 of NIH Stroke Scale.
Timepoint [1] 0 0
90 Days
Secondary outcome [2] 0 0
Changes from baseline to Day 90 of Barthel Index.
Timepoint [2] 0 0
90 Days
Secondary outcome [3] 0 0
Changes from baseline to Day 90 of Modified Rankin Scale.
Timepoint [3] 0 0
90 Days

Eligibility
Key inclusion criteria
1. Subject is >/= 18 years of age

2. Subject has been diagnosed with acute ischemic stroke with onset = 24 hours from
enrollment.

3. Subject has NIH stroke score (NIHSS) = 6 and = 25.

4. Subject or legally authorized representative is willing and able to sign written
informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subject is currently prescribed angiotensin-converting-enzyme inhibitors (ACEi) and is
unable or unwilling to convert to another antihypertensive pharmacological treatment
during the active treatment period (+5 days) of the study.

2. Subject has a history of significant allergic diathesis such as urticaria, angioedema
or anaphylaxis.

3. Subjects with current malignancy or active malignancy = 3 years prior to enrollment
except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer
that has undergone potentially curative therapy and at least six months have elapsed
since the procedure.

4. Subject has a history of clinically significant acute bacterial, viral, or fungal
systemic infections in the last four weeks prior to enrollment.

5. Subject has clinical or laboratory evidence of an active infection at the time of
enrollment.

6. Subject has known alpha 1-antitrypsin deficiency (a1-antitrypsin deficiency).

7. Subject has a known diagnosis of human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screening.

8. Subject is pregnant or nursing.

9. Subject is male or female of childbearing potential, is participating in heterosexual
sexual activity that could lead to pregnancy, and is unable or unwilling to practice
medically effective contraception during the study.

10. Subject is participating in any other investigational device or other drug study = 4
weeks or 5 half-lives of the investigational product, whichever is longer.

11. Subject does not have sufficient venous access for infusion of study treatment or
blood sampling.

12. In the opinion of the Investigator, subject is unlikely to be followed for the
duration of t the study.

13. Subject is unable or unwilling to comply with protocol requirements, including
assessments, tests, and follow-up visits.

14. Subject has any other medical condition which in the opinion of the Investigator will
make participation medically unsafe or interfere with the study results.

15. Pre-stroke Modified Rankin Scale =4

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/01/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/01/2020
Sample size
Target
Accrual to date
Final
92
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Lismore Base Hospital - Lismore
Recruitment hospital [2] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 0 0
John Hunter Hospital - New Lambton Heights
Recruitment hospital [4] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [5] 0 0
Princess Alexandria Hospital - Woolloongabba
Recruitment hospital [6] 0 0
Alfred Health - Melbourne
Recruitment hospital [7] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [8] 0 0
Sunshine Hospital - St Albans
Recruitment hospital [9] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [10] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [11] 0 0
Ballarat Health Services - Ballarat
Recruitment hospital [12] 0 0
Box Hill Hospital - Box Hill
Recruitment postcode(s) [1] 0 0
- Lismore
Recruitment postcode(s) [2] 0 0
- Liverpool
Recruitment postcode(s) [3] 0 0
- New Lambton Heights
Recruitment postcode(s) [4] 0 0
- Herston
Recruitment postcode(s) [5] 0 0
- Woolloongabba
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
3050 - Parkville
Recruitment postcode(s) [8] 0 0
- St Albans
Recruitment postcode(s) [9] 0 0
- Murdoch
Recruitment postcode(s) [10] 0 0
- Adelaide
Recruitment postcode(s) [11] 0 0
- Ballarat
Recruitment postcode(s) [12] 0 0
- Box Hill

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
DiaMedica Therapeutics Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic
stroke patients. The study will be randomized, placebo controlled at multiple centers.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03290560
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bruce Campbell
Address 0 0
Melbourne Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03290560